Efficacy and safety of antiviral therapy for chronic hepatitis C in patients with concomitant diseases

Abstract

Relevance. Eliminating the hepatitis C virus is one of the main tasks for infectious disease specialists.

Objective. To evaluate the efficacy and safety of therapy for chronic hepatitis C (HCV) with glecaprevir/pibrentasvir (GP) in patients with concomitant diseases.

Methods. The results of HCV therapy in 153 patients from 4 groups were analyzed: those without concomitant diseases, with hypertension (GB), with GB and diabetes mellitus (DM), and with cirrhosis of the liver (CL).

Results. There were no differences in the effectiveness of HCV treatment between the patient groups. In patients with DM, blood glucose levels decreased by 6.3% after 2 months of HCV therapy.

Conclusion. HCG therapy with GP is effective in patients without concomitant diseases, such as GB, DM, and compensated CL. Patients with diabetes after HCV treatment should consult an endocrinologist to correct hypoglycemic therapy.